Rates of Nervous System Disorders Following Bortezomib Use in Patients: A Descriptive Analysis Read more about Rates of Nervous System Disorders Following Bortezomib Use in Patients: A Descriptive Analysis
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Cohort Characterization Read more about Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors
Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis Read more about Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis
Utilization of Valsartan: A Descriptive Analysis Read more about Utilization of Valsartan: A Descriptive Analysis
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis Read more about Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis Read more about Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis
Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis Read more about Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis
Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis Read more about Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis
FDA Labeling Change: Vedolizumab & Interstitial Lung Disease (ILD) Read more about FDA Labeling Change: Vedolizumab & Interstitial Lung Disease (ILD)